MedTrace Logo

Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma

NCT06040229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2023-09-15

No results posted yet for this study

Summary

This retrospective study is looking into mechanisms of drug therapy resistance in FFPE samples in recurrent and refractory Rhabdomyosarcoma (RMS) in pediatric patients who have experienced lung recurrence. The study employs advanced techniques such as single-cell transcriptomics and spatial transcriptomics to gain a comprehensive understanding of these mechanisms.

Conditions

  • Alveolar Childhood Rhabdomyosarcoma
  • Embryonal Childhood Rhabdomyosarcoma
  • Recurrent Childhood Rhabdomyosarcoma

Sponsors & Collaborators

  • Shandong Tumor Hospital

    collaborator OTHER

  • Shandong First Medical University

    lead OTHER

Principal Investigators

  • Tao Xu · Shandong First Medical University

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2023-07-01
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06040229 on ClinicalTrials.gov